Description
Lupin Limited and Sun Pharmaceutical clarify they did not receive letters from US President regarding drug pricing as reported in media.
Summary
Two pharmaceutical companies, Lupin Limited and Sun Pharmaceutical Industries Limited, have issued clarifications in response to exchanges’ queries about a news report claiming President Trump sent letters to 17 global drug majors seeking lower prices. Both companies confirmed they did not receive any such letters and stated there is no material impact on their operations.
Key Points
- Lupin Limited confirmed it has not received any letter from the US Government regarding drug pricing
- Sun Pharmaceutical Industries Limited also confirmed it is not among the recipients of any such letter
- Both companies stated they are not aware of any undisclosed information that could explain trading movements
- The news report was general in nature and not company-specific
- Companies clarified there is no material impact on their business operations
Regulatory Changes
No regulatory changes mentioned in this circular.
Compliance Requirements
- Companies responded to stock exchange queries under Regulation 30 of SEBI Listing Regulations
- Both companies reaffirmed their commitment to making prompt disclosures of material information
Important Dates
- August 01, 2025: Date of clarification letters from both companies
- July 31, 2025: Date when US President reportedly sent letters to pharmaceutical companies
Impact Assessment
Minimal impact as both companies confirmed they were not recipients of any US government letters regarding drug pricing. This was a routine clarification exercise in response to media reports that caused market speculation. No operational or financial impact expected on either company.
Impact Justification
Routine clarification response to media reports with no material impact on companies